[1] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2023, 78(6):1966-1986.
[2] 柯思甜, 王辉, 傅君芬. 儿童非酒精性脂肪性肝病更名为代谢相关脂肪性肝病的机遇与挑战[J]. 中华实用儿科临床杂志, 2025, 40(10):787-791.
[3] 中华医学会儿科学分会消化学组, 中国儿童慢性肝病协作组, 中华儿科杂志编辑委员会. 儿童代谢功能障碍相关脂肪性肝病诊治专家共识(2025)[J]. 中华儿科杂志, 2025, 63(9):960-966.
[4] Schwimmer J B, Biddinger S B, Ibrahim S H. MASLD in children:integrating epidemiological trends with mechanistic and translational advances[J]. J Clin Invest, 2025, 135(13):e186422.
[5] Kostrzeba E, Bik-Multanowski M, Brandt-Heunemann S, et al. Pediatric MASLD in severe obesity:current clinical perspectives on diagnosis and treatment[J]. J Clin Med, 2025, 15(1):137.
[6] DiStefano J K. Early-life nutritional determinants of pediatric MASLD[J]. Nutrients, 2025, 17(24):3871.
[7] Goyal N P, Xanthakos S, Schwimmer J B. Metabolic dysfunction-associated steatotic liver disease in children[J]. Gut, 2025, 74(4):669-677.
[8] 张鑫赫, 关琳. 儿童非酒精性脂肪性肝病流行病学现状及防治进展[J]. 中国实用内科杂志, 2024, 44(1):22-28.
[9] Younossi Z M, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease[J]. Clin Mol Hepatol, 2025, 31(Suppl):S32-S50.
[10] Li X, Zhou X D, Wu J, et al. Pediatric MASLD in China:epidemiology, screening, diagnosis, and management[J]. Lancet Reg Health West Pac, 2025, 64:101717.
[11] Ye X, Li X, Zhao Z, et al. Prevalence of hepatic steatosis and increased liver stiffness in Chinese children and adolescents:a national multicenter study[J]. J Intern Med, 2026, 299(4):529-533.
[12] Huneault H E, Tiwari P, Jarrell Z R, et al. Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data[J]. Nat Commun, 2026, 17(1):3107.
[13] Zhang L, El-Shabrawi M, Baur L A, et al. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease[J]. Med, 2024, 5(7):797-815.e792.
[14] Schwimmer J B, Thai N Q N, Noon S L, et al. Long-term mortality and extrahepatic outcomes in 1096 children with MASLD:a retrospective cohort study[J]. Hepatology, 2026, 83(3):561-574.
[15] Alves V P V, Mouzaki M, Xanthakos S A, et al. Longitudinal evaluation of pediatric and young adult metabolic dysfunction-associated steatotic liver disease defined by MR elastography[J]. Eur Radiol, 2025, 35(5):2474-2486.
[16] Lefere S, Koot B G P, Mann J P, et al. Update in clinical science:MASLD in children and adolescents[J]. J Hepatol, 2026, 84(6):1164-1177.
[17] Doycheva I, Issa D, Watt K D, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States[J]. J Clin Gastroenterol, 2018, 52(4):339-346.
[18] Panganiban J, Kehar M, Ibrahim S H, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity:an obesity medicine association (OMA) and expert joint perspective 2025[J]. Obes Pillars, 2025, 14:100164.
[19] Mosca A, Braghini M R, Pietrobattista A, et al. Efficacy of non-pharmacological treatments in pediatric MASLD:a review of the literature[J]. Front Nutr, 2025, 12:1667377.
[20] Zhang P P, Li L, Fu H, et al. Effect of an mHealth-assisted multifaceted lifestyle intervention on body-mass index, hepatic fat content and stiffness in children with overweight or obesity:a cluster randomised controlled trial[J]. eClinicalMedicine, 2026, 94:103840.
[21] Li S, Mao Q. Rethinking risk indices in pediatric MASLD[J]. JHEP Rep, 2025, 7(10):101522.
[22] Stroes A R, Vos M, Benninga M A, et al. Pediatric MASLD:current understanding and practical approach[J]. Eur J Pediatr, 2024, 184(1):29.
[23] 陶丽华, 莫国锃, 李柏林. 饮食和运动干预防治肥胖儿童非酒精性脂肪性肝病的研究进展[J]. 中华肝脏病杂志, 2025, 33(1):93-96.
[24] Jiang L, Du L D, Zeng J, et al. Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome:from research landscape to targeted modulation[J]. Clin Mol Hepatol, 2026, 32(1):53-68. |
